Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Department of Internal Medicine, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA.
Int J Mol Sci. 2021 Mar 9;22(5):2757. doi: 10.3390/ijms22052757.
Obesity, diabetes, and inflammation increase the risk of breast cancer, the most common malignancy in women. One of the mainstays of breast cancer treatment and improving outcomes is early detection through imaging-based screening. There may be a role for individualized imaging strategies for patients with certain co-morbidities. Herein, we review the literature regarding the accuracy of conventional imaging modalities in obese and diabetic women, the potential role of anti-inflammatory agents to improve detection, and the novel molecular imaging techniques that may have a role for breast cancer screening in these patients. We demonstrate that with conventional imaging modalities, increased sensitivity often comes with a loss of specificity, resulting in unnecessary biopsies and overtreatment. Obese women have body size limitations that impair image quality, and diabetes increases the risk for dense breast tis-sue. Increased density is known to obscure the diagnosis of cancer on routine screening mammography. Novel molecu-lar imaging agents with targets such as estrogen receptor, human epidermal growth factor receptor 2 (HER2), pyrimi-dine analogues, and ligand-targeted receptor probes, among others, have potential to reduce false positive results. They can also improve detection rates with increased resolution and inform therapeutic decision making. These emerg-ing imaging techniques promise to improve breast cancer diagnosis in obese patients with diabetes who have dense breasts, but more work is needed to validate their clinical application.
肥胖、糖尿病和炎症会增加乳腺癌的风险,乳腺癌是女性最常见的恶性肿瘤。通过基于影像学的筛查尽早发现是乳腺癌治疗和改善预后的主要方法之一。对于某些合并症患者,可能需要个体化的影像学策略。本文综述了关于肥胖和糖尿病女性中常规影像学检查方法的准确性、抗炎药物在提高检测效果方面的潜在作用以及可能在这些患者的乳腺癌筛查中发挥作用的新型分子影像学技术。我们发现,常规影像学检查方法的敏感性增加往往伴随着特异性降低,导致不必要的活检和过度治疗。肥胖女性的体型限制会影响图像质量,而糖尿病会增加致密乳腺组织的患病风险。已知致密乳腺组织会掩盖常规筛查乳房 X 线摄影的癌症诊断。具有雌激素受体、人表皮生长因子受体 2 (HER2)、嘧啶类似物和配体靶向受体探针等靶点的新型分子影像学试剂有可能减少假阳性结果。它们还可以通过提高分辨率来提高检测率,并为治疗决策提供信息。这些新兴的影像学技术有望改善肥胖合并糖尿病且乳腺致密的乳腺癌患者的诊断,但仍需要更多的工作来验证其临床应用。